31 August 2026 – BeOne Medicines Ltd. announced positive topline results from the second interim analysis (IA2) of the Phase 3 HERIZON-GEA-01 trial evaluating Ziihera (zanidatamab), in combination… read more.
BeOne Medicines Ltd. announced that the FDA has approved the supplemental Biologics License Application (sBLA) for Tevimbra (tislelizumab) in combination with Ziihera (zanidatamab) and chemotherapy for the first-line… read more.
Jazz Pharmaceuticals plc announced that the U.S. Food and Drug Administration (FDA) approved two Ziihera (zanidatamab-hrii)-containing regimens for the first-line treatment of adults with unresectable locally advanced or… read more.
The National Institute for Health and Care Excellence (NICE) has issued six Technology Appraisal decisions between 6 and 20 May 2026, recommending four new treatments for NHS use… read more.
The Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval to Jazz Pharmaceuticals Research UK Limited for zanidatamab (Ziihera) in adults to treat biliary tract cancer whose cancer… read more.
Jazz Pharmaceuticals plc announced that the Committee for Medicinal Products for Human Use (CHMP) of the EMA has adopted a positive opinion recommending the conditional marketing authorization of… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
